BioTek Receives Extraordinary New Product Line Award from Fisher
News Mar 04, 2014
BioTek Instruments, Inc. has received Thermo Fisher Scientific's "Extraordinary New Product Line" award for their Cytation 3 Cell Imaging Multi-Mode Reader.
The award was presented at the Fisher Scientific North America Sales Meeting, held February 24-26, 2014 in Denver, Colorado.
Cytation 3 was recognized by Fisher Scientific's product management team for its innovative technology and successful sales performance.
"We're proud to have Fisher Scientific as a strong partner, and honored to receive this award," noted Gary Barush, Director of Marketing and Sales at BioTek Instruments. "Together, and with Cytation 3's combination of cellular imaging and multi-mode microplate detection, we can continue to provide unique workflow solutions to any laboratory."
BioTek's patent pending Cytation™ 3 Cell Imaging Multi-Mode Reader combines automated digital fluorescence microscopy and conventional microplate detection in a modular and upgradable platform.
This allows for quantitative and phenotypic cellular analyses, and especially for live cell assays where Cytation 3's temperature control and available gas control module support the ideal environment to grow, image, count and further analyze cells in microplates and other sample vessels.
Cytation 3 is the recipient of two additional awards since its launch: MipTec New Product Innovation Award and the SelectScience "Scientists' Choice Award for Best Drug Discovery Product" Award. It is also a finalist in the 2014 Edison Awards® competition.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE